^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    miR-155 expression

    i
    Other names: MIR155, MicroRNA 155, MIRN155
    Entrez ID:
    406947
    Related biomarkers:
    Expression
    CNA
    Others
    11ms
    MIR-155 as a potential biomarker for disease severity in st-segment elevation myocardial infarction: insights from a university-affiliated cardiovascular center. (PubMed, Rev Invest Clin)
    No significant correlation was found between miR-155 and inflammatory or myocardial markers. Dysregulated miR-155 expression in STEMI patients may influence disease severity and MACE risk, independent of inflammation or myocardial damage markers.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR155 (MicroRNA 155)
    |
    miR-155 expression
    11ms
    New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Behçet's disease. (PubMed, Clin Rheumatol)
    •MALAT1/miR-155 are promising biomarkers for Behçet's disease. •MALAT1/miR-155 targets IL-6/TNF-α/CD-106 signaling.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR155 (MicroRNA 155) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    |
    miR-155 expression
    11ms
    Agathisflavone Inhibits Viability and Modulates the Expression of miR-125b, miR-155, IL-6, and Arginase in Glioblastoma Cells and Microglia/Macrophage Activation. (PubMed, Molecules)
    Exposure of human microglia/macrophage to the secretome from GL-15 GMB cells modulated proliferation and morphology, effects that were modulated by agathisflavone treatment. These results demonstrate the effect of flavonoids on the growth of GBM cells, which impacts cells in the microenvironment and can be considered for preclinical studies for adjuvant treatments.
    Journal
    |
    IL6 (Interleukin 6) • MIR155 (MicroRNA 155) • ARG1 (Arginase 1)
    |
    miR-155 expression • IL6 expression
    11ms
    EZH2-mediated downregulation of miR-155-5p contributes to prostate cancer cell malignancy through SMAD2 and TAB2. (PubMed, Kaohsiung J Med Sci)
    Lastly, 5-Aza-CdR regulated miR-155-5p expression by modulating its promoter methylation and influenced the malignant behavior of PCa cells. EZH2 promotes H3K27me3 methylation, repressing miR-155-5p expression, which subsequently upregulates the downstream targets SMAD2 and TAB2 and promotes PCa cell proliferation, epithelial-mesenchymal transition (EMT), migration and invasion.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • MIR155 (MicroRNA 155) • SMAD2 (SMAD Family Member 2)
    |
    miR-155 expression
    11ms
    Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (clinicaltrials.gov)
    P=N/A, N=270, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    MIR155 (MicroRNA 155)
    |
    miR-155 expression
    11ms
    Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    MIR155 (MicroRNA 155) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
    |
    miR-155 expression • NFKB1 expression
    |
    decitabine • pevonedistat (MLN4924)
    11ms
    MicroRNAs and long non-coding RNAs In T-cell lymphoma: Mechanisms, pathway, therapeutic opportunities. (PubMed, Pathol Res Pract)
    Additionally, we explore the evolving function of non-coding RNAs in the pathogenesis of T-cell lymphoma. Furthermore, we discuss the potential of RNA-based therapeutics as a promising treatment strategy.
    Review • Journal • IO biomarker
    |
    MIR155 (MicroRNA 155) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • MIR17 (MicroRNA 17) • MIR223 (MicroRNA 223) • MIR31 (MicroRNA 31) • MIR150 (MicroRNA 150) • MIR29A (MicroRNA 29a)
    |
    miR-155 expression
    11ms
    Evaluating MicroRNAs as Diagnostic Tools for Lymph Node Metastasis in Breast Cancer: Findings from a Systematic Review and Meta-Analysis. (PubMed, Crit Rev Oncol Hematol)
    The meta-analysis returned a pooled a Log2 fold change of 1.50 for miR-155 (upregulated) and -0.53 for miR-34a (downregulated) with no evidence of publication bias, and a low risk of bias and applicability concerns. To conclude, this study names miR-155 and miR-34a as potential diagnostic biomarkers for LNM in BC, although further experimental validation is necessary to confirm these findings and develop non-invasive diagnostic tools for clinical use.
    Retrospective data • Review • Journal
    |
    MIR155 (MicroRNA 155) • MIR34A (MicroRNA 34a-5p)
    |
    miR-155 expression
    12ms
    An NIR-driven biosensor based on the metal-enhanced fluorescence effect and a signal amplification strategy for miRNA detection. (PubMed, RSC Adv)
    The target miRNA-155 was reacted with the new ssDNA1 to amplify the detection signal, with a detection range of 0.5-20 pM and a detection limit of 19.76 fM for miRNA-155. In addition, the fluorescent biosensor has been applied for the analysis of miRNA-155 in serum samples, indicating its good practicality.
    Journal
    |
    MIR155 (MicroRNA 155)
    |
    miR-155 expression
    12ms
    Expression of miR-155 and CEA and VEGF Proteins as Diagnostic Markers in Early Stages of Non-Small Cell Lung Cancer in Peripheral Blood. (PubMed, Tanaffos)
    The statistical comparison of the amount of positive biomarker was performed in two groups and it was shown that there is a statistically significant difference between these two groups (P<0.001). This study showed that miR155 gene and CEA and VEGF proteins are relatively good markers for the diagnosis of non-small cell lung cancer patients in Iranian population.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A) • MIR155 (MicroRNA 155)
    |
    miR-155 expression
    1year
    Evaluation of tumorigenesis-related miRNAs in breast cancer in Egyptian women: a retrospective, exploratory analysis. (PubMed, Sci Rep)
    Additionally, miR-155-5p exhibited a significant upregulation in TNBC and can be used as an indicative marker for TNBC. This study holds significant promise for the development of noninvasive miRNA biomarkers with potential clinical applications.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR155 (MicroRNA 155) • ARID2 (AT-Rich Interaction Domain 2) • MIR200A (MicroRNA 200a) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR205 (MicroRNA 205) • TCF4 (Transcription Factor 4) • MIR124-3 (MicroRNA 124-3)
    |
    miR-155 expression • VEGFA expression
    1year
    Exosomal Delivery of miR-155 Inhibitor can Suppress Migration, Invasion, and Angiogenesis Via PTEN and DUSP14 in Triple-negative Breast Cancer. (PubMed, Curr Med Chem)
    It was found that miR-155 antagomir delivery using exosomes can inhibit migration, invasion, and angiogenesis viaPTEN and DUSP14 in TNBC.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • MIR155 (MicroRNA 155) • DUSP1 (Dual Specificity Phosphatase 1) • USP14 (Ubiquitin Specific Peptidase 14)
    |
    miR-155 expression